Translational gap in glioma research

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 8, 2014, Pages 1110-1120

  Ma, Chi ^a,b   Zhao, Gang ^a   Cruz, Mabel Hilda ^b   Sidén, Åke ^b   Yakisich, Juan Sebastian ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical trial; Glioma; Phenotype; Stem cell theory; Stem cells; Stemness

Indexed keywords

AFLIBERCEPT; BENDAMUSTINE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; GEFITINIB; HYPERICIN; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; LOPINAVIR; METHOTREXATE; NIMUSTINE; PROCARBAZINE; RILOTUMUMAB; RITONAVIR; ROMIDEPSIN; SAGOPILONE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TIPIFARNIB; TOPOTECAN; TRABEDERSEN; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; GLIOBLASTOMA; GLIOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; CANCER STEM CELL; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; GLIOMA; HUMANS; NEOPLASTIC STEM CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907167500     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140825110907     Document Type: Article

References (109)

1. Stupp, R.; Tonn, J.C.; Brada, M.; Pentheroudakis, G. ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2010, 21(Suppl 5), v190-193.
2. Stupp, R.; Mason, W.P.; Van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996.
3. Bonavia, R.; Inda, M.M.; Cavenee, W.K. Furnari, F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res., 2011, 71(12), 4055-4060.
4. Ghose, A.K.; Herbertz, T.; Hudkins, R.L.; Dorsey, B.D.; Mallamo, J.P. Knowledge-Based, central nervous system (CNS) lead selection and lead optimization for cns drug discovery. ACS Chem. Neurosci., 2012, 3(1), 50-68.
5. Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA, 2004, 101(3), 781-786.
6. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res., 2003, 63(18), 5821-5828.
7. Singh, S. K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
8. Murat, A.; Migliavacca, E.; Gorlia, T.; Lambiv, W.L.; Shay, T.; Hamou, M.F.; de Tribolet, N.; Regli, L.; Wick, W.; Kouwenhoven, M.C.; Hainfellner, J.A.; Heppner, F.L.; Dietrich, P.Y.; Zimmer, Y.; Cairncross, J.G.; Janzer, R.C.; Domany, E.; Delorenzi, M.; Stupp, R.; Hegi, M.E. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol., 2008, 26(18), 3015-3024.
9. Sanchez-Martin, M. Brain tumour stem cells: Implications for cancer therapy and regenerative medicine. Curr. Stem Cell Res. Ther., 2008, 3(3), 197-207.
10. Umscheid, C.A.; Margolis, D.J.; Grossman, C.E. Key concepts of clinical trials: A narrative review. Postgrad. Med., 2011, 123(5), 194-204.
11. Anderson, E.; Grant, R.; Lewis, S.C.; Whittle, I.R. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br. J. Neurosurg., 2008, 22(3), 339-349.
12. Shih, A.H.; Holland, E.C. Notch signaling enhances nestin expression in gliomas. Neoplasia, 2006, 8(12), 1072-1082.
13. Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.M.; Eberhart, C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res., 2006, 66(15), 7445-7452.
14. Fouladi, M.; Stewart, C.F.; Olson, J.; Wagner, L.M.; Onar-Thomas, A.; Kocak, M.; Packer, R.J.; Goldman, S.; Gururangan, S.; Gajjar, A.; Demuth, T.; Kun, L.E.; Boyett, J.M.; Gilbertson, R.J. Phase I trial of MK-0752 in children with refractory CNS malignancies: A pediatric brain tumor consortium study. J. Clin. Oncol., 2011, 29(26), 3529-3534.
15. Krop, I.; Demuth, T.; Guthrie, T.; Wen, P.Y.; Mason, W.P.; Chinnaiyan, P.; Butowski, N.; Groves, M.D.; Kesari, S.; Freedman, S.J.; Blackman, S.; Watters, J.; Loboda, A.; Podtelezhnikov, A.; Lunceford, J.; Chen, C.; Giannotti, M.; Hing, J.; Beckman, R.; Lorusso, P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol., 2012, 30(19), 2307-2313.
16. Laterra, J.; Goldstein, G.W. Brain microvessels and microvascular cells in vitro. In The blood brain barrier. Cellular and molecular biology; Pardridge, W. M. Ed, Raven Press: New York, 1993, pp. 1-24.
17. Pitz, M.W.; Desai, A.; Grossman, S.A.; Blakeley, J.O. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J. Neurooncol., 2011, 104(3), 629-638.
18. Hayward, R.M.; Patronas, N.; Baker, E.H.; Vézina, G.; Albert, P.S.; Warren, K.E. Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol., 2008, 90(1), 57-61.
19. Talpaz, M.; Silver, R.T.; Druker, B.J.; Goldman, J.M.; Gambacorti-Passerini, C.; Guilhot, F.; Schiffer, C.A.; Fischer, T.; Deininger, M.W.; Lennard, A.L.; Hochhaus, A.; Ottmann, O.G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F.X.; Fernandes-Reese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H. M.; Sawyers, C.L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99(6), 1928-1937.
20. Lo-Coco, F.; Cicconi, L. History of acute promyelocytic leukemia: A tale of endless revolution. Mediterr. J. Hematol. Infect. Dis., 2011, 3(1), e2011067.
21. Zhou, G.B.; Zhang, J.; Wang, Z.Y.; Chen, S.J.; Chen, Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: A paradigm of synergistic molecular targeting therapy. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2007, 362(1482), 959-971.
22. Iwamoto, F.M.; Lamborn, K.R.; Kuhn, J.G.; Wen, P.Y.; Yung, W.K.; Gilbert, M.R.; Chang, S.M.; Lieberman, F.S.; Prados, M.D.; Fine, H.A. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol., 2011, 13(5), 509-516.
23. Twelves, C.; Campone, M.; Coudert, B.; Van den Bent, M.; De Jonge, M.; Dittrich, C.; Rampling, R.; Sorio, R.; Lacombe, D.; De Balincourt, C.; Fumoleau, P. European Organisation for Research and Treatment of Cancer-Early Clinical Studies Group/New Drug Development Programme. Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann. Oncol, 2002, 13(5), 777-780.
24. Polley, M.Y.; Lamborn, K.R.; Chang, S.M.; Butowski, N.; Clarke, J.L.; Prados, M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol., 2010, 12(3), 274-282.
25. Ballman, K.V.; Buckner, J.C.; Brown, P.D.; Giannini, C.; Flynn, P.J.; LaPlant, B.R.; Jaeckle, K.A. The relationship between six month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro. Oncol., 2007, 9(1), 29-38.
26. Lamborn, K.R.; Yung, W.K.; Chang, S.M.; Wen, P.Y.; Cloughesy, T.F.; DeAngelis, L.M.; Robins, H.I.; Lieberman, F.S.; Fine, H.A.; Fink, K.L.; Junck, L.; Abrey, L.; Gilbert, M.R.; Mehta, M.; Kuhn, J.G.; Aldape, K.D.; Hibberts, J.; Peterson, P.M.; Prados, M.D. North American Brain Tumor Consortium. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro. Oncol., 2008, 10(2), 162-170.
27. Levin, V.A.; Ictech, S.; Hess, K.R. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer, 2007, 22(7), 106.
28. Brandes, A.A.; Franceschi, E.; Gorlia, T.; Wick, W.; Jacobs, A.H.; Baumert, B.G.; Van den Bent, M.; Weller, M.; Stupp, R. European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. Eur. J. Cancer, 2012, 48(6), 896-903.
29. Franceschi, E.; Agati, R.; Brandes, A.A. End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. Exp. Rev. Anticancer Ther., 2011, 11(11), 1713-1717.
30. Cruz, M.; Siden, Å.; Tasat, D.R.; Yakisich, J.S. Are all glioma cells cancer stem cells? J. Cancer Sci. Ther., 2010, 2, 100-106.
31. Cruz, M.H.; Siden, A.; Calaf, G.M.; Delwar, Z.M.; Yakisich, J.S. The stemness phenotype model. ISRN Oncol., 2012, 2012, 392647.
32. Vermeulen, L.; De Sousa E Melo, F.; Richel, D.J.; Medema, J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol., 2012, 13(2), e83-89.
33. Delwar, Z.M.; Avramidis, D.; Siden, Å.; Cruz, M.; Yakisich, J.S. Depletion of drug-surviving glioma cells by a second phase treatment with low concentration of salinomycin. Drugs Ther. Stud., 2011, 1(e7), 21-25.
34. Delwar, Z.M.; Avramidis, D.; Elna, F.; Hua, Y.; Siden, A.; Cruz, M.H.; Paulsson, K.M.; Yakisich, J.S. Cytotoxic effect of menadione: Sodium orthovanadate combination on human glioma cells. Invest. New Drugs, 2011, 30(4), 1302-1310.
35. Vita, M.F.; Nagachar, N.; Avramidis, D.; Delwar, Z.M.; Cruz, M.H.; Siden, Å.; Paulsson, K.M.; Yakisich, J.S. Pankiller effect of prolonged exposure to menadione on glioma cells: Potentiation by vitamin C. Invest. New Drugs, 2011, 29(6), 1314-1320.
36. Ni, C.; Huang, J. Dynamic regulation of cancer stem cells and clinical challenges. Clin. Transl. Oncol., 2013, 15(4), 253-258.
37. Reardon, D.A.; Vredenburgh, J.J.; Desjardins, A.; Peters, K.; Gururangan, S.; Sampson, J.H.; Marcello, J.; Herndon, J.E.N.; McLendon, R. E.; Janney, D.; Friedman, A.H.; Bigner, D.D.; Friedman, H.S. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J. Neurooncol., 2011, 101(1), 57-66.
38. Uhm, J.H.; Ballman, K.V.; Wu, W.; Giannini, C.; Krauss, J.C.; Buckner, J.C.; James, C.D.; Scheithauer, B.W.; Behrens, R.J.; Flynn, P.J.; Schaefer, P.L.; Dakhill, S.R.; Jaeckle, K.A. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int. J. Radiat. Oncol. Biol. Phys., 2011, 80(2), 347-353.
39. Ahluwalia, M.S.; Patton, C.; Stevens, G.; Tekautz, T.; Angelov, L.; Vogelbaum, M.A.; Weil, R.J.; Chao, S.; Elson, P.; Suh, J.H.; Barnett, G.H.; Peereboom, D.M. Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. J. Neurooncol., 2011, 102(2), 317-321.
40. Wolff, J.E.; Kortmann, R.D.; Wolff, B.; Pietsch, T.; Peters, O.; Schmid, H.J.; Rutkowski, S.; Warmuth-Metz, M.; Kramm, C. High dose methotrexate for pediatric high grade glioma: Results of the HIT-GBM-D pilot study. J. Neurooncol., 2011, 102(3), 433-442.
41. Reardon, D.A.; Desjardins, A.; Peters, K.; Gururangan, S.; Sampson, J.; Rich, J.N.; McLendon, R.; Herndon, J.E.; Marcello, J.; Threatt, S.; Friedman, A. H.; Vredenburgh, J.J.; Friedman, H.S. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Neurooncol., 2011, 103(2), 371-379.
42. Neyns, B.; Sadones, J.; Chaskis, C.; Dujardin, M.; Everaert, H.; Lv, S.; Duerinck, J.; Tynninen, O.; Nupponen, N.; Michotte, A.; De, G. J. Phase II study of sunitinib malate in patients with recurrent high grade glioma. Neurooncology, 2011, 103(3), 491-501.
43. Abacioglu, U.; Caglar, H.B.; Yumuk, P.F.; Akgun, Z.; Atasoy, B.M.; Sengoz, M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J. Neurooncol., 2011, 103(3), 585-593.
44. Stummer, W.; Nestler, U.; Stockhammer, F.; Krex, D.; Kern, B.C.; Mehdorn, H.M.; Vince, G.H.; Pichlmeier, U. Favorable outcome in the elderly cohort treated by concomitant temozolomide radio chemotherapy in a multicentric phase II safety study of 5-ALA. J. Neurooncol., 2011, 103(2), 361-370.
45. Bogdahn, U.; Hau, P.; Stockhammer, G.; Venkataramana, N.K.; Mahapatra, A.K.; Suri, A.; Balasubramaniam, A.; Nair, S.; Oliushine, V.; Parfenov, V.; Poverennova, I.; Zaaroor, M.; Jachimczak, P.; Ludwig, S.; Schmaus, S.; Heinrichs, H.; Schlingensiepen, K.H. Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study. Neuro. Oncol., 2011, 13(1), 132-142.
46. Minturn, J.E.; Janss, A.J.; Fisher, P.G.; Allen, J.C.; Patti, R.; Phillips, P.C.; Belasco, J.B. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr. Blood Cancer, 2011, 56(1), 39-44.
47. Lai, A.; Tran, A.; Nghiemphu, P.L.; Pope, W.B.; Solis, O.E.; Selch, M.; Filka, E.; Yong, W.H.; Mischel, P.S.; Liau, L.M.; Phuphanich, S.; Black, K.; Peak, S.; Green, R.; Spier, C.E.; Kolevska, T.; Polikoff, J.; Fehrenbacher, L.; Elashoff, R.; Cloughesy, T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Clin. Oncol., 2011, 29(2), 142-148.
48. Pollack, I.F.; Stewart, C.F.; Kocak, M.; Poussaint, T.Y.; Broniscer, A.; Banerjee, A.; Douglas, J.G.; Kun, L.E.; Boyett, J.M.; Geyer, J.R. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the pediatric brain tumor consortiuM. Neuro Oncol., 2011, 13(3), 290-297.
49. Wen, P.Y.; Schiff, D.; Cloughesy, T.F.; Raizer, J.J.; Laterra, J.; Smitt, M.; Wolf, M.; Oliner, K.S.; Anderson, A.; Zhu, M.; Loh, E.; Reardon, D.A. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro. Oncol., 2011, 13(4), 437-446.
50. Stupp, R.; Tosoni, A.; Bromberg, J. E.; Hau, P.; Campone, M.; Gijtenbeek, J.; Frenay, M.; Breimer, L.; Wiesinger, H.; Allgeier, A.; van den Bent, M. J.; Bogdahn, U.; van der Graaf, W.; Yun, H. J.; Gorlia, T.; Lacombe, D.; Brandes, A. A. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann. Oncol., 2011, 22(9), 2144-2149.
51. Haas-Kogan, D.A.; Banerjee, A.; Poussaint, T.Y.; Kocak, M.; Prados, M.D.; Geyer, J.R.; Fouladi, M.; Broniscer, A.; Minturn, J. E.; Pollack, I.F.; Packer, R.J.; Boyett, J.M.; Kun, L.E. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro. Oncol., 2011, 13(3), 298-306.
52. Grauer, O.; Pascher, C.; Hartmann, C.; Zeman, F.; Weller, M.; Proescholdt, M.; Brawanski, A.; Pietsch, T.; Wick, W.; Bogdahn, U.; Hau, P. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). J. Neurooncol., 2011, 104(3), 801-809.
53. Couldwell, W.T.; Surnock, A.A.; Tobia, A.J.; Cabana, B.E.; Stillerman, C.B.; Forsyth, P.A.; Appley, A.J.; Spence, A.M.; Hinton, D.R.; Chen, T.C. A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer, 2011, 117(21), 4905-4915.
54. Kawabata, S.; Miyatake, S.; Hiramatsu, R.; Hirota, Y.; Miyata, S.; Takekita, Y.; Kuroiwa, T.; Kirihata, M.; Sakurai, Y.; Maruhashi, A.; Ono, K. Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. Appl. Radiat. Isot., 2011, 69(12), 1796-1799.
55. Hegi, M.E.; Diserens, A.C.; Bady, P.; Kamoshima, Y.; Kouwenhoven, M.C.; Delorenzi, M.; Lambiv, W.L.; Hamou, M.F.; Matter, M.S.; Koch, A.; Heppner, F.L.; Yonekawa, Y.; Merlo, A.; Frei, K.; Mariani, L.; Hofer, S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol. Cancer Ther., 2011, 10(6), 1102-1112.
56. Vredenburgh, J.J.; Desjardins, A.; Reardon, D.A.; Peters, K.B.; Herndon, J.E.N.; Marcello, J.; Kirkpatrick, J.P.; Sampson, J.H.; Bailey, L.; Threatt, S.; Friedman, A.H.; Bigner, D.D.; Friedman, H.S. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res., 2011, 17(12), 4119-4124.
57. Reardon, D.A.; Desjardins, A.; Peters, K.B.; Vredenburgh, J.J.; Gururangan, S.; Sampson, J.H.; McLendon, R.E.; Herndon, J.E.; Coan, A.; Threatt, S.; Friedman, A.H.; Friedman, H.S. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer, 2011, 117(23), 5351-5358.
58. De Groot, J.F.; Lamborn, K.R.; Chang, S.M.; Gilbert, M.R.; Cloughesy, T.F.; Aldape, K.; Yao, J.; Jackson, E.F.; Lieberman, F.; Robins, H.I.; Mehta, M.P.; Lassman, A.B.; Deangelis, L.M.; Yung, W.K.; Chen, A.; Prados, M.D.; Wen, P.Y. Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J. Clin. Oncol., 2011, 29(19), 2689-2695.
59. Chamberlain, M.C.; Johnston, S.K. Salvage therapy with single agent bendamustine for recurrent glioblastoma. J. Neurooncol., 2011, 105(3), 523-530.
60. Gállego Pérez-Larraya, J.; Ducray, F.; Chinot, O.; Catry-Thomas, I.; Taillandier, L.; Guillamo, J.S.; Campello, C.; Monjour, A.; Cartalat-Carel, S.; Barrie, M.; Huchet, A.; Beauchesne, P.; Matta, M.; Mokhtari, K.; Tanguy, M.L.; Honnorat, J.; Delattre, J.Y. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial. Clin. Oncol., 2011, 29(22), 3050-3055.
61. Chang, C.N.; Huang, Y.C.; Yang, D.M.; Kikuta, K.; Wei, K.J.; Kubota, T.; Yang, W.K. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J. Clin. Neurosci., 2011, 18(8), 1048-1054.
62. Ananda, S.; Nowak, A.K.; Cher, L.; Dowling, A.; Brown, C.; Simes, J.; Rosenthal, M.A. Cooperative Trials Group for Neuro-Oncology (COGNO). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J. Clin. Neurosci., 2011, 18(11), 1444-1448.
63. Kreisl, T.N.; Zhang, W.; Odia, Y.; Shih, J.H.; Butman, J.A.; Hammoud, D.; Iwamoto, F.M.; Sul, J.; Fine, H.A. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol., 2011, 13(10), 1143-1150.
64. Butowski, N.; Chang, S.M.; Lamborn, K.R.; Polley, M.Y.; Pieper, R.; Costello, J.F.; Vandenberg, S.; Parvataneni, R.; Nicole, A.; Sneed, P.K.; Clarke, J.; Hsieh, E.; Costa, B.M.; Reis, R.M.; Hristova-Kazmierski, M.; Nicol, S.J.; Thornton, D. E.; Prados, M.D. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol., 2011, 13(12), 1331-1338.
65. Khan, R.B.; Raizer, J.J.; Malkin, M.G.; Bazylewicz, K.A.; Abrey, L.E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro. Oncol., 2002, 4(1), 39-43.
66. Stupp, R.; Dietrich, P.Y.; Ostermann Kraljevic, S.; Pica, A.; Maillard, I.; Maeder, P.; Meuli, R.; Janzer, R.; Pizzolato, G.; Miralbell, R.; Porchet, F.; Regli, L.; de Tribolet, N.; Mirimanoff, R. O.; Leyvraz, S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol., 2002, 20(5), 1375-1382.
67. Groves, M.D.; Puduvalli, V.K.; Hess, K.R.; Jaeckle, K.A.; Peterson, P.; Yung, W.K.; Levin, V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol., 2002, 20(5), 1383-1388.
68. Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; Herndon, J.E.N.; Cokgor, I.; McLendon, R.E.; Pegram, C.N.; Provenzale, J.M.; Quinn, J.A.; Rich, J.N.; Regalado, L.V.; Sampson, J.H.; Shafman, T.D.; Wikstrand, C.J.; Wong, T.Z.; Zhao, X.G.; Zalutsky, M.R.; Bigner, D.D. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol., 2002, 20(5), 1389-1397.
69. Viñolas, N.; Gil, M.; Verger, E.; Villá, S.; Pujol, T.; Ceral, L.; García, M.; Graus, F. Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: A phase II study. Anticancer Drugs, 2002, 13(2), 163-167.
70. Turner, C.D.; Gururangan, S.; Eastwood, J.; Bottom, K.; Watral, M.; Beason, R.; McLendon, R.E.; Friedman, A.H.; Tourt-Uhlig, S.; Miller, L.L.; Friedman, H. S. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro. Oncol., 2002, 4(2), 102-108.
71. Robins, H.I.; Chang, S.M.; Prados, M.D.; Yung, W.K.; Hess, K.; Schiff, D.; Greenberg, H.; Fink, K.; Nicolas, K.; Kuhn, J.G.; Cloughesy, T.; Junck, L.; Mehta, M. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro. Oncol., 2002, 4(2), 109-114.
72. Quinn, J.A.; Pluda, J.; Dolan, M.E.; Delaney, S.; Kaplan, R.; Rich, J.N.; Friedman, A.H.; Reardon, D.A.; Sampson, J.H.; Colvin, O.M.; Haglund, M.M.; Pegg, A.E.; Moschel, R.C.; McLendon, R.E.; Provenzale, J. M.; Gururangan, S.; Tourt-Uhlig, S.; Herndon, J.E.I.; Bigner, D.D.; Friedman, H.S. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol., 2002, 20(9), 2277-2283.
73. Levin, V.A.; Yung, W.K.; Bruner, J.; Kyritsis, A.; Leeds, N.; Gleason, M.J.; Hess, K.R.; Meyers, C.A.; Ictech, S. A.; Chang, E.; Maor, M.H. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int. J. Radiat. Oncol. Biol. Phys., 2002, 53(1), 58-66.
74. Ron, I.G.; Gal, O.; Vishne, T.H.; Kovner, F. Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial. Am. J. Clin. Oncol., 2002, 25(3), 296-302.
75. Gururangan, S.; Cavazos, C.M.; Ashley, D.; Herndon, J.E.I.; Bruggers, C.S.; Moghrabi, A.; Scarcella, D.L.; Watral, M.; Tourt-Uhlig, S.; Reardon, D.; Friedman, H.S. Phase II study of carboplatin in children with progressive low-grade gliomas. J. Clin. Oncol., 2002, 20(13), 2951-2958.
76. Raymond, E.; Campone, M.; Stupp, R.; Menten, J.; Chollet, P.; Lesimple, T.; Fety-Deporte, R.; Lacombe, D.; Paoletti, X.; Fumoleau, P. EORTC Early Clinical Studies Group (ECSG); Brain Tumor Studies Group (BTSG); New Drug Development Program (NDDP). Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur. J. Cancer, 2002, 38(10), 1348-1350.
77. Fisher, B.; Won, M.; Macdonald, D.; Johnson, D.W.; Roa, W. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513. Int. J. Radiat. Oncol. Biol. Phys., 2002, 53(4), 980-986.
78. Jennings, M.T.; Sposto, R.; Boyett, J.M.; Vezina, L.G.; Holmes, E.; Berger, M.S.; Bruggers, C.S.; Bruner, J.M.; Chan, K.W.; Dusenbery, K.E.; Ettinger, L.J.; Fitz, C.R.; Lafond, D.; Mandelbaum, D.E.; Massey, V.; McGuire, W.; McNeely, L.; Moulton, T.; Pollack, I.F.; Shen, V. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J. Clin. Oncol., 2002, 20(16), 3431-3437.
79. Brandes, A.A.; Ermani, M.; Basso, U.; Paris, M.K.; Lumachi, F.; Berti, F.; Amistà, P.; Gardiman, M.; Iuzzolino, P.; Turazzi, S.; Monfardini, S. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: A phase II study. Oncology, 2002, 63(1), 38-41.
80. Wick, W.; Hermisson, M.; Kortmann, R.D.; Küker, W. M.; Duffner, F.; Dichgans, J.; Bamberg, M.; Weller, M. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: A phase II study. J. Neurooncol., 2002, 59(2), 151-155.
81. Gilbert, M.R.; Friedman, H.S.; Kuttesch, J.F.; Prados, M.D.; Olson, J.J.; Reaman, G.H.; Zaknoen, S.L. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro. Oncol., 2002, 4(4), 261-267.
82. Kunschner, L.J.; Fine, H.; Hess, K.; Jaeckle, K.; Kyritsis, A.P.; Yung, W.K. CI-980 for the treatment of recurrent or progressive malignant gliomas: National central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest., 2002, 20(7-8), 948-954.
83. Larson, D.A.; Prados, M.; Lamborn, K.R.; Smith, V.; Sneed, P.K.; Chang, S.; Nicholas, K.M.; Wara, W.M.; Devriendt, D.; Kunwar, S.; Berger, M.; McDermott, M.W. Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54(5), 1397-1404.
84. Watanabe, K.; Kanaya, H.; Fujiyama, Y.; Kim, P. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study. Acta Neurochir (Wien)., 2002, 144(12), 1265-1270.
85. Silvani, A.; Eoli, M.; Salmaggi, A.; Erbetta, A.; Fariselli, L.; Boiardi, A. Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. Neurol. Sci., 2002, 23(5), 219-224.
86. Choi, I.S.; Lee, S.H.; Kim, T.Y.; Bang, J.S.; Paek, S.H.; Kim, S.; Kim, I.H.; Heo, D.S.; Bang, Y.J.; Kim, D.G.; Jung, H.W.; Kim, N.K. Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol., 2002, 60(2), 171-176.
87. Spiller, S.E.; Ditzler, S.H.; Pullar, B.J.; Olson, J.M. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J. Neurooncol., 2008, 87(2), 133-141.
88. Lampson, L.A. Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs, 2011, 3(2), 153-160.
89. Folkins, C.; Man, S.; Xu, P.; Shaked, Y.; Hicklin, D.J.; Kerbel, R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res., 2007, 67(8), 3560-3564.
90. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 2006, 5, 67.
91. Gong, X.; Schwartz, P.H.; Linskey, M.E.; Bota, D.A. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology, 2011, 76(13), 1126-1134.
92. Kreisl, T.N.; Kim, L.; Moore, K.; Duic, P.; Kotliarova, S.; Walling, J.; Musib, L.; Thornton, D.; Albert, P.S.; Fine, H.A. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin. Cancer Res., 2009, 15(10), 3617-3623.
93. Griffero, F.; Daga, A.; Marubbi, D.; Capra, M.C.; Melotti, A.; Pattarozzi, A.; Gatti, M.; Bajetto, A.; Porcile, C.; Barbieri, F.; Favoni, R.E.; Lo Casto, M.; Zona, G.; Spaziante, R.; Florio, T.; Corte, G. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J. Biol. Chem., 2009, 284(11), 7138-7148.
94. Kang, K.B.; Zhu, C.; Wong, Y.L.; Gao, Q.; Ty, A.; Wong, M.C. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int. J. Radiat. Oncol. Biol. Phys., 2012, 83(1), e43-52.
95. Blaney, S.M.; Takimoto, C.; Murry, D.J.; Kuttesch, N.; McCully, C.; Cole, D.E.; Godwin, K.; Balis, F.M. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother. Pharmacol., 1998, 41(6), 464-468.
96. Khatri, A.; Gaber, M.W.; Brundage, R.C.; Naimark, M.D.; Hanna, S.K.; Stewart, C.F.; Kirstein, M.N. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemother. Pharmacol., 2011, 68(3), 721-731.
97. Kiewe, P.; Neumann, M.; Wagner, T.; Seyfert, S.; Albrecht, H.; Thiel, E.; Korfel, A. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies. Cancer Chemother. Pharmacol., 2011, 67(1), 27-33.
98. Larkin, J.M.; Hughes, S.A.; Beirne, D.A.; Patel, P.M.; Gibbens, I.M.; Bate, S.C.; Thomas, K.; Eisen, T.G.; Gore, M.E. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br. J. Cancer., 2007, 96(1), 44-48.
99. Edén, A.; Fuchs, D.; Hagberg, L.; Nilsson, S.; Spudich, S.; Svennerholm, B.; Price, R.W.; Gisslén, M. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J. Infect. Dis., 2010, 202(12), 1819-1825.
100. Hau, P.; Dietrich, J.; Fabel, K.; Bogdahn, U. Advances in the therapy of high-grade glioma at relapse: Pegylated liposomal doxorubicin. Exp. Rev. Neurother., 2002, 2(5), 609-615.
101. Angelastro, J.M.; Lamé, M.W. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol. Cancer Res., 2010, 8(8), 1105-1115.
102. Anthonypillai, C.; Sanderson, R.N.; Gibbs, J.E.; Thomas, S.A. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J. Pharmacol. Exp. Ther., 2004, 308(3), 912-920.
103. Hoffmann, J.; Fichtner, I., Lemm, M.; Lienau, P.; Hess-Stumpp, H.; Rotgeri, A.; Hofmann, B.; Klar, U. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol., 2009, 11(2), 158-166.
104. Zhou, Q.; Gallo, J.M. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharma-cokinetic application. J. Pharm. Biomed. Anal., 2010, 51(4), 958-964.
105. Fu, J.; Liu, Z.G.; Liu, X.M.; Chen, F.R.; Shi, H.L.; Pangjesse, C.S.; Ng, H.K.; Chen, Z.P. Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin. Med. J. (Engl), 2009, 122(11), 1255-1259.
106. Cloughesy, T.F.; Wen, P.Y.; Robins, H.I.; Chang, S.M.; Groves, M.D.; Fink, K.L.; Junck, L.; Schiff, D.; Abrey, L.; Gilbert, M.R.; Lieberman, F.; Kuhn, J.; DeAngelis, L.M.; Mehta, M.; Raizer, J.J.; Yung, W.K.; Aldape, K.; Wright, J.; Lamborn, K.R.; Prados, M.D. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J. Clin. Oncol., 2006, 24(22), 3651-3656.
107. Lopez, K.A.; Tannenbaum, A. M.; Assanah, M.C.; Linskey, K.; Yun, J.; Kangarlu, A.; Gil, O.D.; Canoll, P.; Bruce, J.N. Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res., 2011, 71(11), 3963-3971.
108. Domer, F.R.; Smith, M.E. Ethanol decreases entry of vincristine into brain of rat: Modification by acetylcholine or histamine. Proc. Soc. Exp. Biol. Med., 1988, 188(1), 92-95.
109. Yu, S.C.; Ping, Y.F.; Yi, L.; Zhou, Z.H.; Chen, J.H.; Yao, X.H.; Gao, L.; Wang, J.M.; Bian, X.W. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett, 2008, 265(1), 124-134.